Ibex Investors’s AnaptysBio ANAB Stock Holding History

Ibex Investors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,835	Closed	-$176K	–	23
2019 Q4	$176K	Buy	+10,835	New	+$256K	﹤0.01%	53

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ibex Investors's ANAB Position: Q1 2020 in Review

Ibex Investors sold out of AnaptysBio (ANAB) in Q1 2020, closing a stake of 10,835 shares — an estimated $176K sold.

Ibex Investors first reported a position in ANAB in Q4 2019 and held it in 1 quarter. The position peaked at $176K in Q4 2019. 116 funds tracked by Wall St. Rank hold ANAB as of Q1 2020.

Ibex Investors reported no remaining AnaptysBio position as of Q1 2020 after selling out during the quarter.
Ibex Investors sold 10,835 AnaptysBio shares in Q1 2020, an estimated $176K.
Ibex Investors first reported a position in AnaptysBio in Q4 2019 and held it in 1 quarter.
Ibex Investors's AnaptysBio position peaked at $176K in Q4 2019.
116 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2020.

Based on Ibex Investors's 13F filing for Q1 2020, filed 14 May 2020.